# MagnetisMM-7 (elranatamab): what clinicians are saying

> 34 statements from 6 sources (4 videos, 1 post, 1 registry record), 9 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026.

## Report

- Trial: A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
- NCT ID: NCT05317416
- Registry: https://clinicaltrials.gov/study/NCT05317416
- Sponsor: Pfizer
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: elranatamab
- Indication: newly diagnosed multiple myeloma after autologous stem-cell transplantation
- Version: v1.0.0, edition 1
- Accepted: 2026-11-22 UTC
- Last checked: 2026-11-22 UTC
- Release hash: 67a580e655dd94086b2777c68ef0b6e36c11f74c1d88be464fe53470aa8c8979

## Counts

- Commentary sources screened: 13
- Sources cited by verified statements: 6
- Verified statements: 34
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 9
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 6
- Speakers cited: 6
- Cited speakers with a verified identity: 5
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 3
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 3
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 1 physician, Hematology and oncology

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist reads MagnetisMM-7 as challenging maintenance practice, but considers Dara-R arguably more current than lenalidomide alone, with Isa-R only a possibility. In broader safety discussion, another speaker perceives more neuropathy, myalgias and skin reactions with elranatamab than with other bispecifics in practice; that oncologist cites broadly similar reported neurologic rates for elranatamab and teclistamab, noting prior-treatment confounding. The clinicians cited leave duration unresolved; neither comparison establishes maintenance-specific safety, and the sources reviewed for this edition provide no trial outcomes.

## Question clinicians left open

What do clinicians say about whether lenalidomide alone remains the right comparator for elranatamab maintenance in MagnetisMM-7 after autologous transplantation in newly diagnosed multiple myeloma, versus daratumumab–lenalidomide or possibly isatuximab–lenalidomide?

From finding F1 (4 statements from 2 speakers in 3 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Lenalidomide alone: why a clinician questions the post-ASCT maintenance comparator
  - 4 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.
- F3. Maintenance: most clinicians ask how long; one asks about OS and sequencing
  - 7 statements from 3 speakers in 4 sources, 2 of them podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one asks about OS and sequencing”.
  - 2 of the report's 3 cited clinicians.
- F4. Earlier use: a speaker weighs durability vs toxicity; a clinician supports trials
  - 8 statements from 2 speakers in 2 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view; 1 of the 2 holds its caveat, “a clinician supports trials”.
  - 1 of the report's 3 cited clinicians.

### Beyond the trial population

- F2. Elranatamab: where speakers split on relative neuropathy risk
  - 5 statements from 2 speakers in 1 source.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other.
  - 1 of the report's 3 cited clinicians.
- F5. Local care: what speakers say
  - 7 statements from 1 speaker in 1 source, a podcast or video.
  - No named clinician · accounts and unnamed speakers.

2 of the 5 findings and 12 of the 34 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 4 | 5 | 3 | 2 | 2 |
| F3 | 7 | 6 | 4 | 3 | 3 |
| F4 | 8 | 5 | 2 | 2 | 5 |
| F2 | 5 | 2 | 1 | 2 | 3 |
| F5 | 7 | 3 | 1 | 1 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 1 | 1 | 0 | 1 | 1 | 5 | 2 | 1 post or article, 1 podcast or video, 1 registry |
| F3 | 1 | 2 | 0 | 0 | 4 | 8 | 1 | 1 post or article, 2 podcasts and video, 1 registry |
| F4 | 1 | 2 | 0 | 0 | 5 | 10 | 2 | 2 podcasts and video |
| F2 | 1 | 2 | 1 | 1 | 0 | 5 | 0 | 1 post or article |
| F5 | 0 | 0 | 0 | 0 | 7 | 8 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Progression Free Survival: F3 (2 shared claims)
- Secondary endpoints: F3 (3 shared claims)
- Population and setting: F3 (2 shared claims), F4 (2 shared claims)
- The comparison: F1 (3 shared claims), F3 (1 shared claims)
- Safety and tolerability: F3 (1 shared claims)
- Design and conduct: no finding draws on it directly

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 6 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 3 of the 6 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

8 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival | discussed | 2 | 2 |
| Secondary endpoints | discussed | 3 | 2 |
| Population and setting | discussed | 4 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 4 | 3 |
| Safety and tolerability | discussed | 6 | 2 |
| Design and conduct | no commentary found | 0 | 0 |
| Treatment duration, placement and sequencing | discussed | 2 | 2 |
| Earlier-use and cross-study development rationale | discussed | 3 | 2 |
| Community delivery and patient-support constraints | discussed | 7 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 25 statements · 74%** | | | |
| YouTube | 25 | 4 | 4 |
| Podcasts | 0 | 0 | 1 |
| **Posts · 8 statements · 23%** | | | |
| X threads | 8 | 1 | 8 |
| **Primary sources · 1 statement · 3%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2022-04-08 to 2026-11-01
- Cited window: 2022-10-06 to 2026-11-01
- Retrieved: 2026-11-22

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
- Registry: NCT05317416 (https://clinicaltrials.gov/study/NCT05317416)
- Study IDs: C1071007 · MagnetisMM-7 (Alias Study Number) · 2023-508897-27-00 (CTIS (EU))
- Sponsor: Pfizer
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 854 (actual)
- Start: 2022-03-25 (actual)
- Primary completion: 2027-08-04 (estimated)
- Primary endpoint: Progression Free Survival (Assessed for up to approximately 5 years)
- Intervention: Elranatamab (drug)
- Intervention: Lenalidomide (drug)
- Intervention: Lenalidomide (drug)
- Intervention: Elranatamab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 38 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.
- The sources reviewed for this edition are selected public discussions, not a representative sample of HCP opinion. One X thread and four video sources underpin this narrative; multiple statements or reposts should not be counted as independent clinicians.
- Discussion that does not name the trial, uses short acronyms or contains other transcription variants may be missing. An issue not discussed here may nevertheless be discussed elsewhere.
- A standalone protocol document and an exact-trial publication were not identified for this edition. The materials do not provide MagnetisMM-7 outcome data with which to test the expressed expectations or concerns.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The comparative safety impressions and reported neurologic rates lack sufficient population, timing and study detail to establish comparative safety in post-transplant maintenance.
- Some panel remarks cannot be assigned to a named speaker and may have been made by a named participant already represented elsewhere in the discussion.
- General earlier-line and community-delivery observations do not establish MagnetisMM-7 efficacy, toxicity rates, dosing schedules or service requirements.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-22 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-22 UTC. No changes.

## Offer

- Size: Focused · 34 verified statements · 9 from 3 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (5 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/magnetismm-7-nct05317416
- Agents: POST https://www.erudio.com/api/orders with {"report": "magnetismm-7-nct05317416", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=magnetismm-7-nct05317416

## Cite

Erudio Health. MagnetisMM-7 (NCT05317416): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/magnetismm-7-nct05317416

## Questions

### How much does the MagnetisMM-7 report cost?

One edition costs $750 (Focused · 34 verified statements · 9 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the MagnetisMM-7 report cover?

34 statements from 6 sources (4 videos, 1 post, 1 registry record), 9 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the MagnetisMM-7 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "magnetismm-7-nct05317416" }) previews it and create_order({ "report": "magnetismm-7-nct05317416", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the MagnetisMM-7 report?

Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/magnetismm-7-nct05317416.json
- Markdown: https://www.erudio.com/reports/magnetismm-7-nct05317416.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/magnetismm-7-nct05317416/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "magnetismm-7-nct05317416"}`
